

Deferred Registration: Quotient Sciences Code: QSC303709

Submission date 09/06/2026	Recruitment status Not yet recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/06/2026	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/06/2026	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Contact information

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Quotient Sciences, Mere Way, Ruddington Fields, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)

Scientific, Public

Contact name

None Skyhawk Study Doctor

Contact details

180 3rd Ave. Sixth Floor
Waltham
United States of America

MA 02451
+1 (617) 858 0041
brian.yoon@skyhawktx.com

Additional identifiers

Integrated Research Application System (IRAS)
1013851

Quotient Sciences Code
QSC303709

Study information

Scientific Title

Deferred registration: Quotient Sciences Code: QSC303709 [Full scientific title to be added on or before the deferral expiry date]

Study objectives

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required

Ethics approval required

Ethics approval(s)

Submitted 22/05/2026, London - Brent Research Ethics Committee (2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 (0)20 7104 8128; brent.rec@hra.nhs.uk), ref: 26/LO/0337

Primary study design

Interventional

Allocation

N/A: single arm study

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Single

Purpose

Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Completion date

07/09/2026

Eligibility

Key inclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

Yes

Age group

Mixed

Lower age limit

30 Years

Upper age limit

65 Years

Sex

Male

Total final enrolment

0

Key exclusion criteria

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

03/08/2026

Date of final enrolment

07/09/2026

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Quotient Sciences Limited**

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information**Organisation**

Skyhawk Therapeutics, Inc.

Funder(s)**Funder type****Funder Name**

Skyhawk Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available